QIAGEN enhances QIAwave portfolio with new eco-friendlier nucleic acid extraction kits
25 Setembro 2023 - 5:05PM
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
the extension of its eco-friendlier QIAwave product line with the
addition of two new nucleic acid extraction kits: the QIAwave
RNeasy Plus Mini Kit and QIAwave DNA/RNA Mini Kit, eco-friendlier
versions of the RNeasy Plus Mini Kit and the All DNA/RNA Mini Kit.
The kits are designed to provide researchers
with a more sustainable alternative to QIAGEN’s standard kits while
maintaining the same high-quality performance with identical
chemistry.
QIAwave kits use up to 62% less plastic and up
to 58% less cardboard than QIAGEN’s most popular kits for
extracting DNA, RNA and plasmid DNA from samples, making them a
more sustainable choice for laboratories. The QIAwave product line
is the first to use both recycled plastics and space-saving
chemical concentrates. The products feature fewer components, waste
tubes made from 100% recycled plastic, and suitable buffer
concentrates in smaller bottles. More compact kits and new ways of
packing them reduce the amount of cardboard needed for
packaging.
“The launch of the new QIAwave kits not only
expands our eco-friendlier product offerings but also reinforces
our dedication to supporting researchers in their quest for
scientific advancement while reducing their environmental
footprint. At QIAGEN, we’re constantly striving to find innovative
ways to combine high-quality performance with eco-friendlier
solutions,” said Dr. Thomas Schweins, Senior Vice President and
Head of QIAGEN’s Life Sciences Business Area.
Bryce Carpenter, Research Specialist, University
of Pennsylvania, said: “QIAwave offers the same great results for
less clutter and waste, with minimal effort. I can only imagine
that the benefits and savings would be even greater on the scale of
a full lab.”
A tool to calculate how much plastic and
cardboard can be saved by using QIAwave kits as compared to other
QIAGEN kits and more information on the QIAwave portfolio can be
found here:
https://www.qiagen.com/sustainability/environment/more-sustainable-products
The QIAwave RNeasy Plus Mini Kit is a new
generation of RNA extraction that enables the isolation of
high-purity and high-yield total RNA with an integrated gDNA
removal from a wide range of cultured cells and easy-to-lyse
tissues. The QIAwave DNA/RNA Mini Kit allows for simultaneous
purification of genomic DNA and total RNA from each cell or tissue
sample, with the purified DNA and RNA eluted separately.
The new additions to the QIAwave product line
join the previously launched QIAwave RNA Mini Kit, QIAwave DNA
Blood & Tissue Kit, and QIAwave Plasmid Miniprep Kit in
QIAGEN’s growing portfolio of eco-friendlier solutions.
QIAGEN is aiming to reduce its plastic
footprint, in particular by replacing expanded polystyrene (EPS)
boxes for cooled shipments with recyclable alternatives made of
straw and other forms of plastic packaging with more eco-friendly
alternatives. QIAGEN in 2022 reduced its plastic usage in
transportation by 16.5%, nearly double the target for at least a 9%
reduction.
Reducing its plastic footprint is just one
aspect of QIAGEN’s sustainability initiatives. The company is one
of only a few in the pharmaceuticals, life sciences, and
biotechnology sector with a science-based net-zero target validated
by the Science Based Targets initiative, pledging to hit net-zero
greenhouse gas emissions by 2050 from 2020 as the base year. QIAGEN
has been recognized by various rating agencies for its
sustainability efforts, including a “Prime” status by ISS ESG and
an A rating from MSCI ESG Research.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
June 30, 2023, QIAGEN employed more than 6,100 people in over 35
locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, including those
products used in the response to the COVID-19 pandemic, timing for
launch and development, marketing and/or regulatory approvals,
financial and operational outlook, growth and expansion,
collaborations, markets, strategy or operating results, including
without limitation its expected adjusted net sales and adjusted
diluted earnings results, are forward-looking, such statements are
based on current expectations and assumptions that involve a number
of uncertainties and risks. Such uncertainties and risks include,
but are not limited to, risks associated with management of growth
and international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, including the
breadth and duration of the COVID-19 pandemic and its impact on the
demand for our products and other aspects of our business, or other
force majeure events; as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected; and the other factors discussed under the
heading “Risk Factors” contained in Item 3 of our most recent
Annual Report on Form 20-F. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
pr@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024